1Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxonabicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 2003,21 : 963-964.
2Gori S, Mosconi AM, Basurtol C, et al. Weekly paclitaxel in metastatic breast cancer patients: a phase Ⅱ study. Tumori,2002,88:470-473.
3Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanxes in breast and ovarian cancer. Drug Safety, 2000,23:401-428.
4Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981,47:207-214.
5Bonadonna G, Valagussa P. Comment on "The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival". Cancer Treat Rep, 1983,67 : 527-529.
6Seidman AD, Tiersten C, Hudis C, et al. Phase Ⅱ trim of paxlitaxel by 3-hour infusion as initial mad salvage chemotherapy for metastatic breast cancer. J Clin oncol, 1995,13:2575-2581.
7Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol, 2004, 22:2061-2168.
8Citron ML, Berry DA, Cirfincione C, et al. Randomized trim of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 2003, 21:1431-1439.
